Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 12:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 12,233 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Infusion Procedure Clear all
Completed Not applicable Interventional Results available

Using Intravenous Heparin Versus Standard of Care Subcutaneous Heparin to Prevent Clots After Surgery

NCT01608906
View directory record Official record
Conditions
Venous Thrombosis
Interventions
low dose intravenous heparin (LDIVH), Heparin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Sep 26, 2026, 12:42 AM EDT
Recruiting Phase 2 Interventional

Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation

NCT06807606
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Drugs Cyclophosphamide, Fludarabine, Thiotepa, Tacrolimus, Mycophenolate mofetil
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 60 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Completion of Radiation Therapy Alone or Combined Radiation Therapy and Chemotherapy

NCT00738452
View directory record Official record
Conditions
Lung Cancer
Interventions
high performance liquid chromatography, pharmacological study, radionuclide imaging, single photon emission computed tomography, radiation therapy, yttrium Y 90 anti-CEA monoclonal antibody cT84.66
Other · Procedure · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Phase 2 Interventional Results available

Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation

NCT00990249
View directory record Official record
Conditions
Leukemia, Lymphoma, Allogeneic Haematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia
Interventions
Busulfan, Clofarabine, Thymoglobulin, Stem Cell Transplant
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of Gepotidacin in Subjects With Varying Degrees of Renal Impairment and in Subjects With Normal Renal Function

NCT02729038
View directory record Official record
Conditions
Infections, Bacterial
Interventions
Gepotidacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose

NCT05136885
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
SLS-005, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Closed-loop Glucose Control for Automated Management of Type 1 Diabetes

NCT00811317
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Closed-loop
Device
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Phase 2 Interventional

Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function

NCT01794663
View directory record Official record
Conditions
Delayed Graft Function
Interventions
OPN-305, Placebo
Drug
Lead sponsor
Opsona Therapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
14
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Sep 26, 2026, 12:42 AM EDT
Withdrawn Not applicable Interventional

Phenylephrine Dose and Mode of Administration for Spinal Anesthesia Induced Hypotension

NCT02101047
View directory record Official record
Conditions
Complications; Cesarean Section, Spinal Anesthetics Causing Adverse Effects in Therapeutic Use
Interventions
Phenylephrine
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Phase 1 Interventional

Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias

NCT01149915
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, High-risk Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia, Advanced Myelofibrosis
Interventions
TH-302
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Phase 2 Interventional Results available

Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease

NCT01565616
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Conditioning Regimen with Bone Marrow Transplant
Drug
Lead sponsor
Emory University
Other
Eligibility
16 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
8
States / cities
Oakland, California • Washington D.C., District of Columbia • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Phase 1 Interventional

A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days.

NCT00002138
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Tecogalan sodium
Drug
Lead sponsor
Daiichi Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 26, 2026, 12:42 AM EDT
Recruiting Phase 1 Interventional

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

NCT04234048
View directory record Official record
Conditions
T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma, Peripheral T-Cell Lymphoma, Not Classified, Primary Cutaneous T-cell Lymphoma, Cutaneous T-Cell Lymphoma, Unspecified, Cutaneous T-cell Lymphoma, Follicular T-Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Sézary's Disease, Mycosis Fungoides
Interventions
Fenretinide
Drug
Lead sponsor
SciTech Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Phase 1 Interventional

Pentamidine + Salvage Chemo for Relapsed/Refractory Classical Hodgkin Lymphoma

NCT03730363
View directory record Official record
Conditions
Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions
Pentamidine
Drug
Lead sponsor
Reinhold Munker
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A

NCT01580293
View directory record Official record
Conditions
Hemophilia A
Interventions
BAY94-9027
Biological
Lead sponsor
Bayer
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
14
States / cities
Tucson, Arizona • Sacramento, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 26, 2026, 12:42 AM EDT
Terminated Phase 3 Interventional Results available

A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia

NCT01110421
View directory record Official record
Conditions
Pneumonia, Bacterial, Community-Acquired Infections, Nosocomial Infection, Pneumonia, Ventilator-Associated
Interventions
Cefepime placebo, Cefepime, Doripenem, Doripenem placebo, Amoxicillin/clavulanate potassium
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Months to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Little Rock, Arkansas • Cleveland, Ohio • Toledo, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Sep 26, 2026, 12:42 AM EDT
Active, not recruiting Phase 3 Interventional

BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants

NCT05943106
View directory record Official record
Conditions
Non-Muscle- Invasive Bladder Cancer
Interventions
Durvalumab, BCG
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Phase 3 Interventional Results available

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

NCT00917384
View directory record Official record
Conditions
Gastric Cancer, Adenocarcinoma
Interventions
ramucirumab, Placebo, Best Supportive Care (BSC)
Biological · Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
14
States / cities
Bakersfield, California • La Jolla, California • Redlands, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 26, 2026, 12:42 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma

NCT02314052
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
DCR-MYC
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Scottsdale, Arizona • Boston, Massachusetts • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Sep 26, 2026, 12:42 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Dex as Analgesic Adjuvant in OSA Patients

NCT03613558
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Phase 1Phase 2 Interventional

Combination Study of SV-BR-1-GM With Retifanlimab

NCT03328026
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer, Breast Cancer Metastatic
Interventions
SV-BR-1-GM, Low dose cyclophosphamide, Interferon Inoculation, retifanlimab
Biological · Drug
Lead sponsor
BriaCell Therapeutics Corporation
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
14
States / cities
Newport Beach, California • Santa Rosa, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Phase 2 Interventional

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants

NCT06086626
View directory record Official record
Conditions
Gram-Negative Bacterial Infections
Interventions
Cefiderocol, Standard of Care
Drug
Lead sponsor
Shionogi
Industry
Eligibility
Up to 3 Months
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Little Rock, Arkansas • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Red Blood Cell ATP Release and Vascular Function in Humans

NCT03404843
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Fasudil Hydrochloride, Saline
Drug · Other
Lead sponsor
Colorado State University
Other
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Sep 26, 2026, 12:42 AM EDT
Completed Phase 1 Interventional

High Dose Ascorbic Acid for Plasma Cell Disorders

NCT03602235
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ascorbate, Melphalan
Other · Drug
Lead sponsor
Christopher Strouse
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 26, 2026, 12:42 AM EDT